Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

SCLC diagnosis involves imaging, biopsies, and lab tests to assess tumor spread and guide treatment decisions. Treatment options vary by stage, with surgery, chemotherapy, radiation, and immunotherapy ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Ziyafetova, G. (2026) Complete Response in Inoperable Stage IIB Squamous Cell Lung Carcinoma after Sequential Radiotherapy ...

Identification and validation of hypoxia and energy metabolism-related gene signatures in lung adenocarcinoma and their potential implications for immunotherapy. This is an ASCO Meeting Abstract from ...